Premium
Pune-based Emcure Pharmaceuticals’ initial public offering (IPO) will make it the most expensive firm among peers and hand out 26% annualised return on paper to US private equity company Bain Capital, show VCCircle estimates. Emcure recently filed draft papers for an IPO worth Rs 4,000 crore is expected to bestow a ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
